Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated TumorsJaleh Fallah, Julia A. Beaver, William F. Pierce et al.|Clinical Cancer Research|2022Cited by 180
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Richard Pazdur, Michael H. Brave et al.|Clinical Cancer Research|2016Cited by 54
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerYang‐Min Ning, Richard Pazdur, Michael H. Brave et al.|The Oncologist|2015Cited by 42
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael H. Brave, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 29